Clinical Effect of the Combination Therapy of Hydroxychloroquine, Azithromycin and Ivermectin in Patients with COVID-19
Sathi et al.,
Clinical Effect of the Combination Therapy of Hydroxychloroquine, Azithromycin and Ivermectin in Patients with..,
Journal of Cardiovascular Disease Research, doi:10.31838/jcdr.2021.12.05.11
Prospective study of 85 COVID-19 patients including 8 ICU patients treated with ivermectin, HCQ, and AZ, showing all patients improving except for one patient that died 3 days after admission. Authors recommend early treatment. There was no control group.
Sathi et al., 31 Jul 2021, peer-reviewed, 8 authors.
Abstract: Journal of Cardiovascular Disease Research
ISSN:0975-3583,0976-2833
VOL12,ISSUE05,2021
Original Article
Clinical Effect of the Combination Therapy of
Hydroxychloroquine, Azithromycin and Ivermectin in
Patients with COVID-19
SatyanandSathi1, Anil Kumar Garg 1, Amit Mittal2, Savita Verma* 4, Virendra Singh Saini1, Manoj
Kumar Singh1, Devinder Vohra 1 , Sushil Kumar 3
1
Department of Medicine, S.M.M.H. Government Medical College Saharanpur, Uttar Pradesh, India
Department of Community Medicine, S.M.M.H. Government Medical College Saharanpur, Uttar Pradesh,
India
3
Department of Paediatrics,S.M.M.H. Government Medical College Saharanpur, Uttar Pradesh, India
4
M.S. Obstetrics and Gynaecology, S.M.M.H. Government Medical College Saharanpur, Uttar Pradesh, India
*Corresponding author:
Dr. Savita Verma, Assistant Professor, M.S. Obstetrics and Gynaecology, S.M.M.H. Government Medical
College, Ambala Road, Saharanpur, Uttar Pradesh, India,
Email : Savita.sathi@gmail.com
2
Abstract
Background: The ongoing pandemic has highlighted the need for an effective treatment of COVID-19 patients
and prevention of SARS-CoV-2 community transmission.Methods: We conducted a prospective observational
study on a cohort of 85 COVID-19 patients (80% males, median age 46 years, range 18–80 years). Patients were
treated with a triple drug therapy: ivermectin 12 mg once a week, hydroxychloroquine 400 mg twice a day on
the first day and 200 mg twice a day for the next 4 days, and azithromycin 500 mg once a day for 5 days.
Endpoints were assessed by clinical outcomes, death, negative SARS-CoV-2 RNA-PCR test on the tenth day,
and length of the hospital stay.Results: All patients improved except one 70-year-old female, who died on the
third day of admission. The clinical outcome was considered good as 95.24% (80/84) of patients presented a
negative SARS-CoV-2 RNA-PCR test on the tenth day of admission and 90.48% (76/84) were discharged in
stable condition.Conclusions: The response must focus on immediate isolation of COVID-19 patients and their
early treatment to prevent irreversible severe respiratory injury. Our study shows the beneficial effect of triple
drug therapy in terms of clinical recovery, shorter duration of viral carriage, community spread prevention, and
minimal cost of therapy.
KeywordsHydroxychloroquine, Azithromycin, Ivermectin, COVID-19 patients
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit